Rankings
▼
Calendar
LIVN
LivaNova PLC
$3B
Q2 2024 Earnings
Healthcare
Medical - Devices
Income Statement
Revenue
$319M
+8.4% YoY
Gross Profit
$215M
67.4% margin
Operating Income
$40M
12.6% margin
Net Income
$16M
5.1% margin
EPS (Diluted)
$0.30
QoQ Revenue Growth
+8.0%
Cash Flow
Operating Cash Flow
$43M
Free Cash Flow
$31M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$2.5B
Total Liabilities
$1.2B
Stockholders' Equity
$1.2B
Cash & Equivalents
$329M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$319M
$294M
+8.4%
Gross Profit
$215M
$205M
+4.7%
Operating Income
$40M
$17M
+131.2%
Net Income
$16M
$1M
+1314.1%
Revenue Segments
Cardiopulmonary Segment
$174M
55%
Neuromodulation Segment
$143M
45%
Geographic Segments
UNITED STATES
$180M
56%
Locations Excluding The United States And Europe
$88M
28%
Europe
$51M
16%
← FY 2024
All Quarters
Q3 2024 →
LIVN Q2 2024 Earnings — LivaNova PLC Revenue & Financial Results | Market Cap Arena